Shire receives complete-response letter for Intuniv

07/28/2009 | Reuters

The FDA deferred its approval decision on extended-release Intuniv, Shire's drug candidate for attention-deficit/hyperactivity disorder, because of unresolved labeling discussions. Shire said the company remains confident that the treatment will be approved in the fourth quarter.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT